RecruitingPhase 1NCT07064005

Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

Brain Glutathione (GSH) Enrichment Through Gamma-glutamylcysteine (GGC) Supplementation in Early Parkinson's Disease Patients for Reduction of Extrapyramidal Motor Disturbances and Halting Cognition Decline: A Pilot Trial

Sponsor

Pravat Mandal

Enrollment

12 participants

Start Date

Mar 20, 2026

Study Type

INTERVENTIONAL

Conditions

Parkinsons Disease (PD)

Summary

This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation. 2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation 3. To study impact of GGC on gut health on the PD patients.

Eligibility

Min Age: 50 YearsMax Age: 80 Years

Inclusion Criteria4

Confirmed Parkinson's Disease diagnosis.
Montreal Cognitive Assessment (MoCA) greater than or equal to 26.
Age (50 to 80 years of age).
Ability to read and write in English.

Exclusion Criteria8

Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body.
Subjects with claustrophobia.
Patients with a clinical diagnosis of Parkinson's disease dementia or dementia with Lewy bodies.
Subjects with a history of cancer.
Subjects with active psychosis or delirium.
Subjects with chronic kidney (creatinine \> 1.5mg/dL) or liver disease (AST ≥ 1.5 ULN; ALT ≥ 1.5 ULN) within 30 days prior to enrolment.
Subjects on antioxidant therapy (ashwagandha, gingko biloba or N-acetylcysteine) or illicit drug abuse/dependence (cocaine, heroin, marijuana, or fentanyl).
Subjects with previous traumatic head injury.